Skip to main content

ERRATUM article

Front. Oncol., 30 October 2014
Sec. Thoracic Oncology
Volume 4 - 2014 | https://doi.org/10.3389/fonc.2014.00300

Erratum: Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)

This article is an erratum on:

  1. Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)

    1. Read original article
Frontiers Production Office*Frontiers Production Office*
  • Frontiers Production Office, Frontiers, Switzerland

An erratum on

Chemotherapy in metastatic NSCLC – new regimens (pemetrexed, nab-paclitaxel)
by Blais N, Hirsh V. Front Oncol (2014) 4:177. doi:10.3389/fonc.2014.00177

Reason for Erratum

In Table 2, the Median OS values (in months) in the column ≥70 years were changed due to a typesetting error. This error does not change the scientific conclusions of the article in any way. The publisher apologizes for this error and the correct version of Table 2 appears below.

TABLE 2
www.frontiersin.org

Table 2. Select efficacy outcomes from the Phase III trial of nab-paclitaxel plus carboplatin in NSCLC.

Keywords: metastatic, non-small cell lung carcinoma, solvent-based paclitaxel, nab-paclitaxel, pemetrexed, histology, clinical trials

Citation: Frontiers Production Office (2014) Erratum: Chemotherapy in metastatic NSCLC – new regimens (pemetrexed, nab-paclitaxel). Front. Oncol. 4:300. doi: 10.3389/fonc.2014.00300

Received: 14 October 2014; Accepted: 14 October 2014;
Published online: 30 October 2014.

Approved by: Oncology Editorial Office, Frontiers, Switzerland

Copyright: © 2014 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: production.office@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.